3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Hepatocellular
42
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Carcinoma, Renal Cell
26
Endometrial Neoplasms
13
Melanoma
10
Neoplasms
8
Uterine Cervical Neoplasms
7
Cholangiocarcinoma
7
Biliary Tract Neoplasms
7
Liver Neoplasms
6
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Neuroendocrine Tumors
5
Triple Negative Breast Neoplasms
4
Thyroid Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Thyroid Carcinoma, Anaplastic
3
Recurrence
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Diabetes Mellitus, Insulin-Dependent, 12
3
Carcinoma, Adenoid Cystic
3
Breast Neoplasms
3
Brain Neoplasms
3
Adenocarcinoma
3
Vulvar Neoplasms
2
Interventions
Gemcitabine
15
Cisplatin
15
pembrolizumab
9
Oxaliplatin
7
durvalumab
5
Leucovorin
5
Fluorouracil
5
130-nm albumin-bound paclitaxel
5
Platinum
4
Albumin-Bound Paclitaxel
4
1,2-diaminocyclohexaneplatinum II citrate
4
Trastuzumab
3
Taxes
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Capecitabine
3
zanidatamab
2
fludarabine
2
Paclitaxel
2
Nivolumab
2
Folfox protocol
2
Docetaxel
2
Cyclophosphamide
2
Biopsy
2
tucatinib
1
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
tivozanib
1
pertuzumab
1
peposertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
lenvatinib
×
1 year
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled